UBS O'Connor’s Capricor Therapeutics CAPR Stock Holding History

UBS O'Connor’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-33,000	Closed	-$43.7K	–	314
2025 Q2	$43.7K	Buy	+33,000	New	+$349K	﹤0.01%	329

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS O'Connor's CAPR Position: Q3 2025 in Review

UBS O'Connor sold out of Capricor Therapeutics (CAPR) in Q3 2025, closing a stake of 17,054 shares — an estimated $169K sold.

UBS O'Connor first reported a position in CAPR in Q3 2024 and held it in 3 quarters. The position peaked at $1.45M in Q4 2024. 115 funds tracked by Wall St. Rank hold CAPR as of Q3 2025.

UBS O'Connor reported no remaining Capricor Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 17,054 Capricor Therapeutics shares in Q3 2025, an estimated $169K.
UBS O'Connor first reported a position in Capricor Therapeutics in Q3 2024 and held it in 3 quarters.
UBS O'Connor's Capricor Therapeutics position peaked at $1.45M in Q4 2024.
115 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.